Verve Therapeutics, Inc.

Historical 13F Holders

Symbol
VERV
CUSIP
92539P101
All holders as of
Q4 2025
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 92539P101 since 12/18/2024, largest first.

Filer % of Class Filed
Pentwater Capital Management LP 13G
7.5% 8/14/2025
Event 6/30/2025
BlackRock, Inc. 13G/A 7.0% 4/17/2025
Event 3/31/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
Millennium Management LLC 13G
4.9% 4/29/2025
Event 4/22/2025
State Street Corp 13G 3.8% 2/5/2025
Event 12/31/2024
ARK Investment Management LLC 13G/A 0% 1/10/2025
Event 9/30/2024
Biotechnology Value Fund L P 13G/A
0% 8/14/2025
Event 6/30/2025
GV 2017, L.P. 13G/A
0% 7/28/2025
Event 7/25/2025

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2025 Q4 1 24.0 k $344k
2025 Q3 7 241 k $1.37M
2025 Q2 177 73.0 M $819M
2025 Q1 193 80.8 M $369M
2024 Q4 168 78.7 M $444M
2024 Q3 177 75.3 M $365M
2024 Q2 168 76.1 M $372M
2024 Q1 165 81.6 M $1.08B
2023 Q4 160 74.7 M $1.04B
2023 Q3 139 63.9 M $847M
2023 Q2 122 61.9 M $1.16B
2023 Q1 127 63.3 M $912M
2022 Q4 124 62.6 M $1.21B
2022 Q3 129 60.7 M $2.08B
2022 Q2 102 45.6 M $696M
2022 Q1 94 46.6 M $1.06B
2021 Q4 97 45.2 M $1.66B
2021 Q3 74 38.7 M $1.81B
2021 Q2 70 37.7 M $2.25B